-
公开(公告)号：US20220153856A1
公开(公告)日：2022-05-19
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20240124597A1
公开(公告)日：2024-04-18
申请号：US18453691
申请日：2023-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20210054090A1
公开(公告)日：2021-02-25
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
Patent Agency Ranking
公开(公告)号：US20240239909A1
公开(公告)日：2024-07-18
申请号：US18441998
申请日：2024-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P37/00 , C07K16/46 , C12N15/63 , A61K39/00 , A61K45/06 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K2039/505 , A61K45/06 , A61K47/6803 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220169742A1
公开(公告)日：2022-06-02
申请号：US17670223
申请日：2022-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, Jr. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220144962A1
公开(公告)日：2022-05-12
申请号：US17579468
申请日：2022-01-19
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20200157233A1
公开(公告)日：2020-05-21
申请号：US16686596
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20170158757A1
公开(公告)日：2017-06-08
申请号：US15364612
申请日：2016-11-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan SRINIVASAN , Shrikant DESHPANDE , Qihong ZHAO , Huadong SUN , Ginger RAKESTRAW , Guodong CHEN , Richard Y. HUANG , Steven SHERIFF , Cristian RODRIGUEZ , John P. THROUP , Rose A. DIBELLA
CPC classification number: C07K16/24 , A61K9/0019 , A61K47/6845 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
